You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Peptide Receptor RadionuclideTherapy

Showing 1 - 25 of 9,629
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroendocrine Tumors, Peptide Receptor Radionuclide Therapy Trial in Rotterdam (olaparib)

Recruiting
  • Neuroendocrine Tumors
  • Peptide Receptor Radionuclide Therapy
  • Rotterdam, South Holland, Netherlands
    Erasmus MC
May 19, 2023

Glucagon-like Peptide-1 Receptor Agonists According to Type 2

Recruiting
  • Diabetes Mellitus, Type 2
  • GLP-1 receptor agonist
  • Bari, Italy
    Azienda Ospedaliero-Universitaria Policlinico Bari
Nov 4, 2023

Caveolin 1 Deficiency in Response to Glucagon-like Peptide 1

Not yet recruiting
  • Overweight and Obesity
  • 24-hour ambulatory blood pressure
  • Liberal salt diet
  • (no location specified)
Oct 4, 2023

Bronchial and Thymic Neuroendocrine Tumour, Paraganglioma/ Phaeochromocytoma, Medullary Thyroid Carcinoma Trial (Lu-177 DOTATATE

Not yet recruiting
  • Bronchial and Thymic Neuroendocrine Tumour
  • +3 more
  • Lu-177 DOTATATE (Lutathera®)
  • (no location specified)
Nov 1, 2023

Preoperative Prandial State of Patients Taking Glucagon-Like

Recruiting
  • Pulmonary Aspiration
  • Gastric ultrasound
  • Houston, Texas
    The University of Texas Health Science Center at Houston
Jun 6, 2023

Metastatic Malignant Tumor in the Liver, Neuroendocrine Tumor Trial in San Francisco (procedure, biological, device)

Recruiting
  • Metastatic Malignant Neoplasm in the Liver
  • Neuroendocrine Neoplasm
  • Arterial Embolization
  • +3 more
  • San Francisco, California
    University of California, San Francisco
Dec 22, 2022

Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine

Not yet recruiting
  • Digestive System Neuroendocrine Tumor G1
  • +5 more
  • Tumor Debulking
  • +5 more
  • Nashville, Tennessee
    Vanderbilt University/Ingram Cancer Center
Aug 23, 2023

Stroke, Stroke, Acute, Stroke, Ischemic Trial in Linyi, Hong Kong (Semaglutide)

Recruiting
  • Stroke
  • +3 more
  • Linyi, Shangdong, China
  • +1 more
Jun 24, 2023

Glucagon-like Peptide 1 Receptor Agonists and Mental Health

Not yet recruiting
  • Diabetes Mellitus
  • +2 more
  • GLP-1 receptor agonist
  • (no location specified)
Aug 4, 2022

Neuroendocrine Tumors, Meningioma, Neuroblastoma Trial in Iowa City (radiation, diagnostic test, drug)

Active, not recruiting
  • Neuroendocrine Tumors
  • +3 more
  • 90Y-DOTA tyr3-Octreotide
  • +2 more
  • Iowa City, Iowa
    University of Iowa Hospitals and Clinics
Oct 6, 2022

AminoMedixTM for Kidney Protection During Radionuclide Therapy

Completed
  • Radiation Nephropathy
    • (no location specified)
    Mar 22, 2023

    Formyl Peptide Receptor 1 With Sepsis-related Encephalopathy

    Not yet recruiting
    • Sepsis-Associated Encephalopathy
      • Yinchuan, Ningxia, China
        Department of Anesthesiology, General Hospital of Ningxia Medica
      Jul 8, 2022

      Pancreatic Neuroendocrine Tumor, Pancreas Cancer Trial in Chicago (cytoreductive surgery, Lutathera - a small molecule used in

      Not yet recruiting
      • Pancreatic Neuroendocrine Tumor
      • Pancreas Cancer
      • cytoreductive surgery
      • +2 more
      • Chicago, Illinois
        The University of Chicago
      Nov 8, 2022

      Carotid Atherosclerosis Trial in Saint Louis (Cu[64]-25%-CANF-Comb PET-MR)

      Completed
      • Carotid Atherosclerosis
      • Cu[64]-25%-CANF-Comb PET-MR
      • Saint Louis, Missouri
        Washington University in St.Louis
      Oct 13, 2022

      Prostate Specific Antigens, Prostate Tumors Trial run by the National Cancer Institute (NCI) (TARP peptide vaccine, TARP

      Completed
      Has Results
      • Prostate Specific Antigens
      • Prostate Neoplasms
      • T-cell receptor alternate reading frame protein (TARP) peptide vaccine
      • T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine
      • Bethesda, Maryland
        National Institutes of Health Clinical Center, 9000 Rockville Pi
      Sep 15, 2022

      Merkel Cell Carcinoma Trial (Pembrolizumab, Lutetium Lu 177 dotatate)

      Not yet recruiting
      • Merkel Cell Carcinoma
      • (no location specified)
      Oct 12, 2022

      HRQoL During PRRT in Patients With NETs

      Completed
      • Neuroendocrine Tumors
      • +2 more
        • (no location specified)
        Jun 16, 2022

        Pancreatic Neuroendocrine Tumor Trial in Milano (peptide receptor radionuclide therapy with Y-90-DOTATOC)

        Recruiting
        • Pancreatic Neuroendocrine Tumor
        • peptide receptor radionuclide therapy with Y-90-DOTATOC
        • Milano, Italy
        • +1 more
        Sep 30, 2022

        Asthma Trial in Nashville (Semaglutide Pen Injector 2.4mg weekly, Placebo)

        Not yet recruiting
        • Asthma
        • Semaglutide Pen Injector 2.4mg weekly
        • Placebo
        • Nashville, Tennessee
          Vanderbilt University Medical Center
        Jun 22, 2022

        Neuroblastoma Trial in Lille, Lyon, Toulouse (PRRT with 177Lu-DOTATATE)

        Not yet recruiting
        • Neuroblastoma
        • PRRT with 177Lu-DOTATATE
        • Lille, France
        • +2 more
        Nov 8, 2022

        Semi-automated Segmentation Methods of SSTR PET for Dosimetry

        Not yet recruiting
        • Refractory Meningioma
        • To evaluate the SUVmean (Standard Uptake Value) as a predictive factor of the tumor absorbed dose compared to the SUVmax
        • (no location specified)
        Sep 8, 2022

        Bilateral Breast Carcinoma, Breast Inflammatory Carcinoma, Stage IB Breast Cancer AJCC v7 Trial in United States (drug, other,

        Active, not recruiting
        • Bilateral Breast Carcinoma
        • +11 more
        • Scottsdale, Arizona
        • +11 more
        Jan 12, 2023

        Nasopharyngeal Carcinoma Trial in Xiamen (177Lu-EB-LM3 1, 177Lu-EB-LM3 2)

        Recruiting
        • SSTR2-positive Tumors
        • 177Lu-LNC1010 1
        • +2 more
        • Xiamen, China
          The First Affiliated Hospital of Xiamen University
        Nov 20, 2022

        (PRRT) for the Treatment of Neuroendocrine Tumors

        Enrolling by invitation
        • Neuroendocrine Tumors
        • Peptide Receptor Radionuclide Therapy
        • Dallas, Texas
          Methodist Dallas Medical Center
        Oct 27, 2021

        Wolfram Syndrome Trial (Tirzepatide)

        Not yet recruiting
        • Wolfram Syndrome
        • (no location specified)
        Dec 12, 2022